The Effects of Nicorandil on Angina Pectoris: Evaluation by a Double-Blind Cross-Over Study.
10.4070/kcj.1986.16.1.103
- Author:
Woong Ku LEE
;
Gil Ja SHIN
;
Yang Soo JANG
;
Keum Soo PARK
;
Nam Sik CHUNG
;
Seung Yun CHO
;
Won Heum SHIM
- Publication Type:Original Article
- MeSH:
Angina Pectoris*;
Blood Pressure;
Cardiology;
Chest Pain;
Cross-Over Studies*;
Electrocardiography;
Female;
Headache;
Heart;
Heart Rate;
Humans;
Male;
Nicorandil*
- From:Korean Circulation Journal
1986;16(1):103-112
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
The effect of oral nicorandil were evaluated by a 9-day double-blind cross-over protocol on 16 subjects with angina pectoris referred to our cardiology clinic from June '84 through September '85. total daily doses were 15-45mg. The effects were measured by 3 seperate treadmill exercise EKG tests and symptom reviews on each patient. The following results were obtained. 1) The mean age of the patients was 57.4+/-7.2 years. These were 14 male and 2 female patients. 2) Resting heart rate on nicorandil was 73.6+/-14.0 beats/min and 70.5+/-14.0 beats/min in placebo(P<0.05). There were no significant effects of nicorandil on resting blood pressure and heart rate-blood pressure product. 3) Peak exercise heart rate was 126.4+/-22.5 beats/min on nicorandil and 121.8+/-21.4 beats/min on placebo(P<0.05). There were no significant effects of nicorandil on blood pressure after exercise and peak heart rate-blood pressure product(x10(-3)) after nocorandil was 20.2+/-5.0 and 18.9+/-4.6 on placebo(P>0.05). 4) Exercise duration was 485.8+/-107.7 sec on nicorandil and 423.3+/-101.9 sec on placebo(P<0.001). 5) The exercise duration was prolonged in 11 cases(68.7%), showed on change in 2 cases(12.5%), and shortened in 3(18.8%). 6) There were attacks of chest pain during placebo period in 2 cases, but none developed during nicorandil period. 7) Headache was noted in 2 patients, and in one of them, it was so severe as to discontinue nicorandil stydy. No other side effects were noted. In conclusion, additional therapeutic benefit can be obtained by nicorandil in patients with severe angina in spite of conventional antianginal agents already being administered.
